TS 106細(xì)胞

數(shù)量： 大量

ATCC Number： HB-12497?

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 小鼠

運(yùn)輸方式： 凍存運(yùn)輸

器官來(lái)源： 脾

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

細(xì)胞形態(tài)： **樣

**類型： mouse IgG1 kappa

Designations: TS 106

TS 106細(xì)胞Depositors: National Cancer Institute

Isotype: mouse IgG1 kappa

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)

Morphology: lymphoblast

Source: Organ: spleen

Cell Type: hybridoma: B lymphocyte;

Cellular Products: immunoglobulin; monoclonal antibody; against human thymidylate synthase (TS)

Permits/Forms: TS 106細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Comments: Animals were immunized with recombinant human thymidylate synthase (TS).

Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.

The antibody reacts specifically with the human protein TS and displays negligible cross-reactivity with other cellular proteins found in human cells. [57566]

The antibody may be used in immunohistochemical, Western Blot, and ELISA assays to detect TS in human colon cell lines. [57566]

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

TS 106細(xì)胞Temperature: 37.0°C

Growth Conditions: Attached cells must be shaken loose or scraped.

Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml.

Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 56271: Johnson PG, et al. Monoclonal antibodies specific for human thymidylate synthase. US Patent 6,221,620 dated Apr 24 2001

57566: Johnson PG, et al. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. TS 106細(xì)胞Cancer Res. 51: 6668-6676, 1992. PubMed: 1720706

57567: Johnson PG, et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 52: 4306-4312, 1992. PubMed: 1643628

57569: Edler D, et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin. Cancer Res. 6: 1378-1384, 2000. PubMed: 10778966

57570: Edler D, et al. Immunohistochemical determination of thymidylate synthase in colorectal cancer--methodological studies. Eur. J. Cancer 33: 2278-2281, 1997. PubMed: 9470819

57571: Edler D, et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin. Cancer Res. 6: 488-492, 2000. PubMed: 10690528